Paclitaxel

规格

33069-62-4CAS 号

608-826-9EC 号

[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoateIUPAC 名称

C47H51NO14化学式

853.9 g/mol分子量

paclitaxel; TAXOL; 33069-62-4; Yewtaxan; Taxol A; Plaxicel; Genaxol; Genetaxyl; Ebetaxel; Capxol; Paxene; OncoGel; Genexol; Intaxel; Mitotax; Pacliex; Onxol; TaxAlbin; Cyclopax; Paxceed; Onxal; Zisu; EmPAC; Taxus Liberte; Taxus stent; Tocosol Paclitaxel; (-)-Paclitaxel; Padexol; Taxus; EndoTAG 1; LEP-ETU; NSC-125973; Nanoxel; Paclitaxol; Sindaxel; Coroflex Please; Cypher select; Taxus Express; DHP-107; MBT 0206; P88XT4IS4D; BMS-181339-01; NSC125973; Infinnium; DTXSID9023413; DHP 107; Bris Taxol; Abraxane I.V. Suspension; BMS 181339-01; 7 epi Taxol; NK 105; NK-105; Paclitaxel (taxus canadensis); NSC 125973; QW 8184; QW-8184; PACITAXEL; Liposome-entrapped paclitaxel easy-to-use; Taxol 100; IG 001; 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; DTXCID603413; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; CHEBI:45863; ABRAXANE COMPONENT PACLITAXEL; ABI-007 COMPONENT PACLITAXEL; NAB-PACLITAXEL COMPONENT PACLITAXEL; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-; paclitaxelum; Taxol, Bris; ((1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo(11.3.1.03,10.04,7)heptadec-13-en-2-yl) benzoate; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-(((2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl)oxy)-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo(11.3.1.0^(3,10).0^(4,7))heptadec-13-en-2-yl benzoate; RefChem:6096; PACLITAXEL PACLITAXEL; L01CD01; PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND; Paclitaxel protein-bound particles for injectable suspension (albumin-bound); (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-(((2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl)oxy)-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo(11.3.1.03,10.04,7)heptadec-13-en-2-yl benzoate; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,1-2alpha,12aalpha,12balpha))-; Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; Abraxane; LipoPac; Genexol-PM; ABI-007; MFCD00869953; Paclitaxel (Taxol); HSDB 6839; ABI 007; DRG-0190; MBT-0206; Paclitaxel, Taxus brevifolia; CHEMBL428647; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate; 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.; NCGC00164367-01; C47H51NO14; nab-paclitaxel; M02242; Cynviloq; Xorane; Taxol (Paclitaxel); (NAB)-Paclitaxel; SMR000857385; EndoTAG-1; SR-01000075350; UNII-P88XT4IS4D; Anzatax; Nanotaxel; Paclical; Pacligel; Paxoral; Praxel; l diacetate; Paclitaxel?; CCRIS 8143; Anzatax;; Paclitaxel CRS; Paclitaxel HCL; Paclitaxel [USAN:USP:INN:BAN]; Abraxane (TN); [diacetoxy-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-dihydroxy-tetramethyl-oxo-[?]yl] benzoate; Paclitaxel; 5beta,20-Epoxy-1,7beta-dihydroxy-9-oxotax-11-ene-2alpha,4,10beta,13alpha-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate]; Taxol; Docetaxel Anhydrous Impurity F; Docetaxel Impurity F; Taxol A;; CAS-33069-62-4; APEALEA; APEXELSIN; NAVERUCLIF; PAZENIR; Paclitaxel (natural); BMS-181339; Paclitaxel-SSMM-VIP; Paclitaxel (Standard); P-SSMM-VIP; PACLITAXEL [MI]; PACLITAXEL [INN]; PACLITAXEL [JAN]; Prestwick3_000155; PACLITAXEL [HSDB]; PACLITAXEL [USAN]; Paclitaxel, semi-synthetic; TAXOL (TN); PACLITAXEL [VANDF]; Paclitaxel (semi-synthetic); PACLITAXEL [MART.]; SCHEMBL3976; Nova-12005; PACLITAXEL [USP-RS]; PACLITAXEL [WHO-DD]; BIDD:PXR0046; BSPBio_000290; KBioGR_002509; KBioSS_002517; Paclitaxel (JAN/USP/INN); MLS002154218; MLS002695976; OAS-PAC-100; PACLITAXEL [EMA EPAR]; BPBio1_000320; GTPL2770; MEGxp0_001940; orb1310120; orb3140975; Taxol (TN) (Bristol Meyers); PACLITAXEL [GREEN BOOK]; SHANGHAI FUDAN-ZHANGJIANG; PACLITAXEL [ORANGE BOOK]; ACon1_002231; HY-B0015R; KBio2_002509; KBio2_005077; KBio2_007645; KBio3_002987; ANX-513; DHP-208; DTS-301; PACLITAXEL [EP MONOGRAPH]; PACLITAXEL [USP IMPURITY]; SDP-013; cMAP_000068; ORAXOL COMPONENT PACLITAXEL; HMS2090D07; HMS2095O12; HMS2231A16; HMS3712O12; PACLITAXEL [USP MONOGRAPH]; Paclitaxel, from Taxus yunnanensis; Abraxane (albumin-bound suspension); HY-B0015; MPI-5018; PACLITAXEL COMPONENT OF NAB-; Tox21_112107; BDBM50001839; EBC-06097; MSK000431; NSC745099; Paclitaxel; Docetaxel EP Impurity F; ABI 007 COMPONENT PACLITAXEL; PACLITAXEL COMPONENT OF ORAXOL; AKOS007930675; AKOS015969673; AKOS025312303; CCG-220155; CS-1145; DB01229; FP10637; GS-6554; NSC-745099; PACLITAXEL COMPONENT OF ABRAXANE; NCGC00164367-02; NCGC00164367-03; NCGC00164367-04; NCGC00164367-05; NCGC00164367-10; PACLITAXEL COMPONENT OF ABI 007; PACLITAXEL COMPONENT OF ABI-007; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; NCI60_000601; SY016928; Paclitaxel, from Taxus yannanensis, powder; 10.BETA.,13.ALPHA.- HEXAHYDROXY-; AB00513812; P0093; Paclitaxel natural for peak identification CRS; D00491; EN300-117275; N88686; AB00513812-02; AB00513812-03; .BETA.-(BENZOYLAMINO)- .ALPHA.-HYDROXY-; Q423762; 7,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.; Paclitaxel semi-synthetic for system suitability CRS; Q-201533; SR-01000075350-1; SR-01000075350-3; SR-01000075350-6; SR-01000075350-7; SR-01000075350-9; 5.BETA.,20-EPOXY-1,2.ALPHA.,4,7.BETA.; BRD-K62008436-001-03-1; BRD-K62008436-001-05-6; BRD-K62008436-001-22-1; Paclitaxel semi-synthetic for peak identification CRS; Paclitaxel, from semisynthetic (from Taxus sp.), >=97%; Paclitaxel Working Standard (Secondary Reference Standard); Paclitaxel, European Pharmacopoeia (EP) Reference Standard; Paclitaxel, from Taxus brevifolia, >=95% (HPLC), powder; H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diy; Paclitaxel, United States Pharmacopeia (USP) Reference Standard; 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; Paclitaxel, Pharmaceutical Secondary Standard; Certified Reference Material; 4,10-DIACETATE 2- BENZOATE,13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE; 7,11-METHANO-5H-CYCLODECA[3,4]BENZ[1,2-B]OXETE BENZENEPROPANOIC ACID DERIV.; Paclitaxel 7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete benzenepropanoic acid deriv.; Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard; (2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro 4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano 5Hcyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate,; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-(benzoylamino)-a-hydroxybenzenepropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12; (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; ,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; ,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)- (9CI); -cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(aR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetoxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl]benzoate; [2AR- [2A.ALPHA.,4.BETA.,4A.BETA.,6.BETA.,9.ALPHA.(ALPHA. R*,.BETA.S*),11.ALPHA.,12.ALPHA.,12A.ALPHA.,12B.ALPHA.]]-TAX-11-EN-9-ONE; 1203669-79-7; 4,10beta-Bis(acetyloxy)-13alpha-{[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy}-1,7beta-dihydroxy-9-oxo-4alpha,5beta-5,20-epoxytax-11-en-2alpha-yl benzoate; 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; 6,12B-BIS(ACETYL OXY)-12-(BENZOYLOXY)- 2A,3,4,4A,5,6,9,10,11,12,12A,12B,- DODECAHYDRO-4,11- DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO- 7,11-METHANO- 1H-CYCLODECA[3,4]BENZ[1,2-B]OXET-9-YL ESTER; BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,4)BENZ(1,2-B)OXET-9-YL ESTER, (.ALPHA.R,.BETA.S)-; Benzenepropanoic acid, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-; Benzenepropanoic acid, b-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,bS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2a-alpha,4-beta,4a-beta,6-beta,9-alpha(alpha-R*,beta-S*),11-alpha,12-alpha,12a-alpha, 12b-alpha))-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-; Paclitaxel semi-synthetic for peak identification, European Pharmacopoeia (EP) Reference Standard; Paclitaxel semi-synthetic for system suitability, European Pharmacopoeia (EP) Reference Standard; PACLITAXELANZATAXTAXOLTAXOL (REGISTERED TRADEMARK)7,11-METHANO-5H-CYCLODECA[3,4]BENZ[1,2-B]OXETE,BENZENEPROPANOIC ACID DERIV.BENZENEPROPANOIC ACID; Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha- hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (8CI); Tax-11-en-9-one,20-epoxy-1,2.alpha.,4,7.beta., 10.beta.,13.alpha.- hexahydroxy-, 4,10-diacetate 2- benzoate,13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine同义词